Table 2.
Difference between groups according to G3-G4 irAE interruption
| No irAE interruption | irAE interruption | p | |
|---|---|---|---|
| PS ECOG | |||
| 0 | 94 | 12 | 0.182 |
| 1 | 72 | 5 | |
| 2 | 18 | 1 | |
| IMDC score | |||
| Good | 55 | 1 | 0.027 |
| Intermediate | 116 | 17 | |
| Poor | 13 | 0 | |
| Sex | |||
| M | 129 | 10 | 0.154 |
| F | 51 | 8 | |
| Synchronous metastatic disease | |||
| Y | 85 | 10 | 0.448 |
| N | 99 | 8 | |
| Lung metastasis | |||
| Y | 75 | 13 | 0.014 |
| N | 61 | 5 | |
| Liver metastasis | |||
| Y | 19 | 3 | 0.759 |
| N | 117 | 15 | |
| Brain metastasis | |||
| Y | 10 | 2 | 0.576 |
| N | 126 | 16 | |
| Gland metastasis | |||
| Y | 28 | 2 | 0.340 |
| N | 108 | 16 | |
| Peritoneal metastasis | |||
| Y | 8 | 0 | 0.367 |
| N | 176 | 18 | |
| IO | |||
| Anti-PD1 | 176 | 12 | < 0.0001 |
| Anti-PD1+ anti CTLA4 | 8 | 6 | |
Y: YES; N: No; irAEs: immune-related Adverse Events; IO: Immune-Oncology; IMDC: score International Metastatic RCC Database Consortium; ECOG PS: Eastern Cooperative Oncology Group Performance Status; anti-PD1: anti programmed death 1; anti-CTLA4: anti-Cytotoxic T-Lymphocyte Antigen 4